Laurent Peyrin-Biroulet

发表

Additional benefit of procalcitonin to C‐reactive protein to assess disease activity and severity in Crohn’s disease

L. Peyrin-Biroulet, A. Oussalah, V. Laurent, 2010, Alimentary pharmacology & therapeutics.

Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.

L. Peyrin-Biroulet, X. Roblin, E. D. Tedesco, 2015, Journal of Crohn's & colitis.

Anti-TNF therapy in inflammatory bowel diseases: a huge review.

L. Peyrin-Biroulet, Laurent Peyrin-Biroulet, 2010, Minerva gastroenterologica e dietologica.

Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease

G. Rogler, A. Schoepfer, A. Straumann, 2015, Alimentary pharmacology & therapeutics.

Systematic review: the financial burden of surgical complications in patients with ulcerative colitis

J. Lindsay, L. Peyrin-Biroulet, A. Bergman, 2015, Alimentary pharmacology & therapeutics.

Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience

B. Flourié, X. Hébuterne, J. Filippi, 2013, Alimentary pharmacology & therapeutics.

Infliximab for refractory ulcerative proctitis

B. Flourié, L. Siproudhis, L. Peyrin-Biroulet, 2010, Alimentary pharmacology & therapeutics.

Long‐term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis

P. Rutgeerts, S. Hanauer, G. Van Assche, 2018, Alimentary pharmacology & therapeutics.

Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel

S. Ng, C. O'Morain, M. Silverberg, 2016 .

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease

P. Seksik, J. Colombel, Laurent Peyrin-Biroulet, 2017, Alimentary pharmacology & therapeutics.

BOWEL DAMAGE AS ASSESSED BY THE LÉMANN INDEX IS REVERSIBLE ON ANTI-TNF THERAPY FOR CROHN'S DISEASE Short title: Bowel damage is reversible on anti-TNF in Crohn's disease

G. Fiorino, M. Allocca, A. Malesci, 2015 .

The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients

V. Laurent, I. Chary-Valckenaere, A. Blum, 2014, Alimentary pharmacology & therapeutics.

Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression

L. Peyrin-Biroulet, P. Sogni, J. Nousbaum, 2008, Alimentary pharmacology & therapeutics.

Factors associated with pregnancy outcome in anti‐TNF treated women with inflammatory bowel disease

A. Amiot, B. Bonaz, M. De Vos, 2014, Alimentary pharmacology & therapeutics.

Post‐operative complications in elderly onset inflammatory bowel disease: a population‐based study

G. Savoye, B. Pariente, H. Sarter, 2018, Alimentary pharmacology & therapeutics.